Contrave^TM: novel treatment for obesity

Bibliography

• Flegal KM, Graubard BI, Williamson DF, Gail MH: Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298(17), 2028–2037 (2007).
   Google Scholar
• Wolf AM, Colditz GA: Current estimates of the economic cost of obesity in the United States. Obes. Res. 6(2), 97–106 (1998).
   Google Scholar
• Finkelstein EA, Fiebelkorn IC, Wang G: State-level estimates of annual medical expenditures attributable to obesity. Obes. Res. 12(1), 18–24 (2004).
   Google Scholar
• Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. National Institutes of Health. Obes. Res.(Suppl. 2), 51S舑209S (1998).
   Google Scholar
• Palamara KL, Mogul HR, Peterson SJ, Frishman WH: Obesity: new perspectives and pharmacotherapies. Cardiol. Rev. 14(5), 238–258 (2006). n General overview of novel emerging pharmaceutical approaches to treating obesity.
   Google Scholar
• Jefferson JW: Bupropion extended-release for depressive disorders. Expert Rev. Neurother. 8(5), 715–722 (2008).
   Google Scholar
• Anton RF: Naltrexone for the management of alcohol dependence. N. Engl. J. Med. 359(7), 715–721 (2008). n General overview of central neural pathways regulating energy intake and expenditure.
   Google Scholar
• Adan RA, Tiesjema B, Hillebrand JJ et al.: The MC4 receptor and control of appetite. Br. J. Pharmacol. 149(7), 815–827 (2006).
   Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M et al.: Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17(1), 30–39 (2009). nn Key experimental study and proof-ofconcept clinical study demonstrating synergistic actions of the bupropion and naltrexone components of ContraveTM on reducing appetite and promoting energy expenditure.
   Google Scholar
• Tong Y, Pelletier G: Role of dopamine in the regulation of proopiomelanocortin (POMC) mRNA levels in the arcuate nucleus and pituitary gland of the female rat as studied by in situ hybridization. Brain Res. Mol. Brain Res. 15(1–2), 27–32 (1992).
   Google Scholar
• Hasegawa H, Meeusen R, Sarre S et al.: Acute dopamine/norepinephrine reuptake inhibition increases brain and coretemperature in rats. J. Appl. Physiol. 99(4),1397–1401 (2005).
   Google Scholar
• Billes SK, Cowley MA: Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 32(4), 822–834 (2007).
   Google Scholar
• Billes SK, Cowley MA: Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 33(6), 1287–1297 (2008).
   Google Scholar
• Gadde KM, Xiong GL: Bupropion for weight reduction. Expert Rev. Neurother. 7(1), 17–24 (2007).
   Google Scholar
• Fantino M, Hosotte J, Apfelbaum M: An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am. J. Physiol. 251(1 Pt 2), R91–R96 (1986).
   Google Scholar
• Parker LA, Maier S, Rennie M, Crebolder J: Morphine- and naltrexone-induced modification of palatability: analysis by the taste reactivity test. Behav. Neurosci. 106(6), 999–1010 (1992).
   Google Scholar
• Atkinson RL, Berke LK, Drake CR et al.: Effects of long-term therapy with naltrexone on body weight in obesity. Clin. Pharmacol. Ther. 38(4), 419–422 (1985).
   Google Scholar
• Mitchell JE, Morley JE, Levine AS et al.: High-dose naltrexone therapy and dietary counseling for obesity. Biol. Psychiatry 22(1), 35–42 (1987).
   Google Scholar
• Clayton AH: Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin. Pharmacother. 8(4), 457–466 (2007).
   Google Scholar
• Croop RS, Faulkner EB, Labriola DF: The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch. Gen. Psychiatry 54(12), 1130舑1135 (1997).
   Google Scholar
• Faulconbridge LF, Wadden TA, Berkowitz RI et al.: Changes in symptoms of depression with weight loss: results of a randomized trial. DOI: 10.1038/oby.2008.647 Obesity (2009) (Epub ahead of print).
   Google Scholar